<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90564">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707953</url>
  </required_header>
  <id_info>
    <org_study_id>RH-4074-OJ1</org_study_id>
    <secondary_id>2012-002572-13</secondary_id>
    <nct_id>NCT01707953</nct_id>
  </id_info>
  <brief_title>Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty</brief_title>
  <official_title>Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty - a Randomized, Placebo Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the efficacy of 5 mg Midodrine (Gutron) vs. placebo on
      reducing the incidence of orthostatic hypotension during mobilization 6 h after a total hip
      arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Orthostatic hypotension</measure>
    <time_frame>6 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Orthostatic hypotension (OH) during early mobilization 6 hours after end of surgery. OH is classified according to international consensus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Orthostatic hypotension 24 hours after surgery</measure>
    <time_frame>24 hours after end of surgery.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Intolerance</measure>
    <time_frame>6 and 24 hours after end of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Orthostatic intolerance is defined as subjective presyncopal symptoms (dizziness, nausea etc.) during mobilization after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment side effects</measure>
    <time_frame>6 and 24 hours after end of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The following side effects to Midodrine are evaluated:
Pruritus
Headache
Supine hypertension
Urinary retention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Haemodynamic response to mobilization 6 and 24 hours after surgery</measure>
    <time_frame>6 and 24 hours after end of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Haemodynamic response to mobilization (supine, sitting and standing):
Response in systolic and diastolic blood pressure
Response in heart rate.
Response in calculated haemodynamic variables (stroke volume, peripheral resistance)</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>before surgery, 6- and 24 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heart rate variability measures including spectral analysis and LF/HF ratio at rest and during mobilization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Orthostatic Hypotension</condition>
  <condition>Postoperative Orthostatic Intolerance</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as capsule 5- and 23 hours after end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).</description>
    <arm_group_label>Midodrine</arm_group_label>
    <other_name>Gutron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule to mimic midodrine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for primary unilateral hip arthroplasty

          -  Age &gt;= 18 years

          -  Able to give informed consent

        Exclusion Criteria:

          -  General anaesthesia for the current procedure

          -  Digoxin treatment.

          -  history of renal or hepatic failure

          -  history of glaucoma

          -  history chronic urinary retention requiring treatment

          -  history of orthostatic intolerance / hypotension

          -  other autonomous nervous system disease

          -  alcohol or drug abuse

          -  current malignant disease

          -  females in the fertile age (possible pregnancy or breast feeding)

          -  Treatment with anticoagulants

          -  BMI &gt; 40 kg/m2

          -  Dementia or cognitive dysfunction (investigators evaluation)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Kehlet, Proffessor</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Section for Surgical Pathophysiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oeivind Jans, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Section for Surgical Pathophysiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte Hospital, Department of orthopaedic surgery</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital, Department of orthopaedic surgery</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus, Department of orthopedic surgery</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Oeivind Jans</investigator_full_name>
    <investigator_title>M.D, Research Fellow</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Neurocirculatory Asthenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
